Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medt | The case is one of several intellectual property disputes between the medtech giant and Axonics—which is currently waiting to become a subsidiary of Boston Scientific.
Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...
Medtronic PLC closed $2.15 below its 52-week high ($91.49), which the company reached on September 4th.
"Medtronic’s Aurora EV-ICD to challenge Boston Scientific’s S-ICD market leadership" was originally created and published by ...
Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...
Medtronic may be an underrated beneficiary of declining interest rates. That's because as rates come down, it becomes less ...
Shares of Medtronic PLC MDT slumped 0.56% to $88.13 Wednesday, on what proved to be an all-around dismal trading session for ...
Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback